سعر لينفيما 4 مجم 30 كبسولة 2025

Lenvatinib 4 mg hard capsules (Lenvima, Eisai), an oral multikinase inhibitor used in thyroid, kidney, liver and endometrial cancers.

• Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC) in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of advanced renal cell carcinoma (RCC) in adults, in combination with pembrolizumab.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Advanced renal cell carcinoma in adults after one prior anti-angiogenic therapy, in combination with everolimus.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (30% or more) in DTC: hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia, abdominal pain and dysphonia.International label, same product · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hypertension: control blood pressure before starting; withhold for grade 3 and discontinue for life-threatening hypertension.International label, same product · DailyMed (U.S. National Library of Medicine)
• Cardiac dysfunction, arterial thromboembolic events, hemorrhagic events and QT interval prolongation have occurred.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity, including hepatic failure, renal failure or impairment, and proteinuria have occurred; monitor and withhold or discontinue as directed.International label, same product · DailyMed (U.S. National Library of Medicine)

• QT-prolonging drugsAvoid co-administration with medicinal products that prolong the QT/QTc interval.DailyMed (U.S. National Library of Medicine)

• Based on animal findings and its mechanism of action, lenvatinib can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 30 days after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment and for 1 week after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Lenvatinib: Inhibits the kinase activities of VEGF receptors VEGFR1-3, FGF receptors FGFR1-4, PDGFRalpha, KIT and RET (US LENVIMA label). The capsules contain lenvatinib mesylate; strength is expressed as lenvatinib.